John Sourbeer
Stock Analyst at UBS
(0.84)
# 4,052
Out of 5,241 analysts
44
Total ratings
47.62%
Success rate
-15.2%
Average return
Main Sectors:
Stocks Rated by John Sourbeer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYRX Cryoport | Maintains: Buy | $11 → $13 | $13.14 | -4.87% | 7 | Nov 5, 2025 | |
| ILMN Illumina | Maintains: Neutral | $110 → $120 | $142.54 | -15.81% | 6 | Oct 31, 2025 | |
| WST West Pharmaceutical Services | Maintains: Buy | $320 → $355 | $302.89 | +17.20% | 5 | Oct 24, 2025 | |
| QGEN Qiagen | Maintains: Neutral | $46 → $48 | $32.98 | +44.39% | 5 | Aug 7, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Buy | $170 → $240 | $116.38 | +106.22% | 2 | Jul 25, 2025 | |
| STVN Stevanato Group | Maintains: Neutral | $24 → $24 | $17.99 | +30.63% | 2 | Mar 7, 2025 | |
| QDEL QuidelOrtho | Maintains: Neutral | $43 → $45 | $10.32 | +336.05% | 4 | Feb 13, 2025 | |
| PACB Pacific Biosciences of California | Downgrades: Neutral | $2 | $1.12 | +78.57% | 3 | Nov 11, 2024 | |
| MEDP Medpace Holdings | Maintains: Buy | $452 → $480 | $415.27 | +15.59% | 4 | Mar 8, 2024 | |
| BRKR Bruker | Maintains: Buy | $94 → $102 | $42.88 | +137.87% | 3 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $21.20 | +135.85% | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $142 → $128 | $84.47 | +51.53% | 2 | Jul 27, 2022 |
Cryoport
Nov 5, 2025
Maintains: Buy
Price Target: $11 → $13
Current: $13.14
Upside: -4.87%
Illumina
Oct 31, 2025
Maintains: Neutral
Price Target: $110 → $120
Current: $142.54
Upside: -15.81%
West Pharmaceutical Services
Oct 24, 2025
Maintains: Buy
Price Target: $320 → $355
Current: $302.89
Upside: +17.20%
Qiagen
Aug 7, 2025
Maintains: Neutral
Price Target: $46 → $48
Current: $32.98
Upside: +44.39%
ICON Public Limited Company
Jul 25, 2025
Maintains: Buy
Price Target: $170 → $240
Current: $116.38
Upside: +106.22%
Stevanato Group
Mar 7, 2025
Maintains: Neutral
Price Target: $24 → $24
Current: $17.99
Upside: +30.63%
QuidelOrtho
Feb 13, 2025
Maintains: Neutral
Price Target: $43 → $45
Current: $10.32
Upside: +336.05%
Pacific Biosciences of California
Nov 11, 2024
Downgrades: Neutral
Price Target: $2
Current: $1.12
Upside: +78.57%
Medpace Holdings
Mar 8, 2024
Maintains: Buy
Price Target: $452 → $480
Current: $415.27
Upside: +15.59%
Bruker
Mar 1, 2024
Maintains: Buy
Price Target: $94 → $102
Current: $42.88
Upside: +137.87%
Feb 2, 2023
Initiates: Neutral
Price Target: $50
Current: $21.20
Upside: +135.85%
Jul 27, 2022
Maintains: Buy
Price Target: $142 → $128
Current: $84.47
Upside: +51.53%